Kontour Medical(SH:688314)2024-11-07 10:14Group 1: Financial Performance - The company's profit significantly decreased in Q4 2022 and Q4 2023 due to increased expenses from annual performance bonuses [1][2] - The company reported no cash collection pressure and maintains a healthy cash flow [2] - The profit growth in Q3 2023 was primarily driven by the successful implementation of bulk purchasing in neurosurgery, leading to increased revenue from PEEK material products [2] Group 2: Dividend and Future Plans - The company has established a stable cash dividend plan to return value to investors [3] - Future dividend plans will be based on the company's profitability and cash flow status [2][3] Group 3: International Expansion - The U.S. subsidiary, BIOPLATE, is part of the company's global strategy, focusing on overseas R&D, production, and sales [3] - Despite current losses, measures are being taken to expand revenue and improve operational efficiency [3] - The localization of PEEK material production in the U.S. is progressing well, with expectations to shorten delivery times and enhance competitiveness in the overseas market [3][4]